PARIS — Clinical acceptance of transcatheter aortic valve implants (TAVI) is driving powerful growth in the structural heart segment of the cardiac market, exclusively in Europe for the moment where the procedure is approved and reimbursement is progressively arriving. (Medical Device Daily) Read More
